OncoSec Medical Inc (ONCSQ)

[hschlauch]

With a negative predictive value of 100% based on peer reviewed and validated published data, the Oncosec and UCSF phase 2 melanoma combination trial should not be observing any responses. The UCSF is using flow cytometry to intentionally select metastatic melanoma patients that are under the 20% pd-1/ctla-4 relative abundance threshold. NO PATIENT SHOULD THEORETICALLY BE RESPONDING, YET WE HAVE THIS PUBLIC INFORMATION...

Cancer Network: ONCOLOGY Journal


"Currently, a phase II clinical trial (ClinicalTrials.gov identifier: NCT02493361) at the University of California, San Francisco (UCSF) is assessing the potential synergy between intratumoral IL-12 (given on days 1, 5, and 8 every 6 weeks) and concurrent administration of pembrolizumab (200 mg every 6 weeks). One 69-year-old female patient in the UCSF trial, with stage IV melanoma and an accessible lesion of the left inner arm, after 2 cycles of IL-12 and 4 cycles of pembrolizumab experienced a positron emission tomography (PET)/computed tomography (CT)–confirmed complete response of the target lesion, and had no other sites of disease by the fifth cycle of treatment. Another female patient in the same trial (72 years old), with a treatable melanoma of the left forearm, after 4 cycles of IL-12 and 10 cycles of pembrolizumab experienced > 98% shrinkage in lesion size from baseline, based on Response Evaluation Criteria in Solid Tumors (RECIST). The most remarkable case in this cohort, however, is that of a 62-year-old male patient with at least stage III melanoma of multiple primary sites who experienced a complete clinical resolution of all treated subcutaneous lesions after only 1 cycle of IL-12 and 2 cycles of pembrolizumab."

ONCOSEC'S ELECTROPORATED IL-12 PLATFORM APPEARS TO BE INCREASING THE RELATIVE FREQUENCIES OF PD-1/CTLA-4-POSITIVE TUMOR INFILTRATING LYMPHOCYTES, SO MUCH SO THAT PREDICTED NON-RESPONDERS ARE ACTUALLY RESPONDING TO ANTI-PD-1 DRUGS. FOLKS, THESE PATIENTS SHOULD NOT BE RESPONDING IN THE PHASE II COMBINATION METASTATIC MELANOMA TRIAL. DOES ANYONE ELSE SEE WHAT IS GOING ON HERE?!